BACKGROUND: Combination chemotherapy with UFT and @entity900 is active and less toxic for advanced @entity1149 . This treatment is likely to be applied to concurrent chemoradiotherapy for locally advanced @entity1149 , especially in the outpatient setting. @entity1 AND METHODS: Ten @entity1 with unresectable @entity5 received the UFT plus @entity900 treatment combined with concurrent radiotherapy. The chemotherapeutic regimen consisted of oral administration of UFT 400 mg/m2 daily and venous infusion of @entity900 20-25 mg/m2 on days 8-10. The administration of @entity900 was repeated every 3-4 weeks. @entity1514 radiation started on day 8, and was completed to a total dose of 60-70 Gy. RESULTS: Adverse events (grade 3 or 4) occurred in 2 @entity1 ( @entity2910 2, @entity1431 / @entity1398 1) with no treatment-related @entity204 . There were 7 partial responses (response rate 70.0%; 95% C.I., 41.6-98.4%). The median survival time was 18.7 months with a 1-year survival rate of 77.8%. Two @entity1 uneventfully received the treatment in an outpatient setting. CONCLUSION: With regard to the quality of life of @entity1 , UFT plus @entity900 with concurrent radiotherapy might be the treatment of choice for unresectable @entity5 .

[UFT plus @entity900 with concurrent radiotherapy in unresectable XXXX --its application to outpatient practice].

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III non-small cell lung cancer'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1514 :: ('MESH:D013896', 'Disease') :: ['Thoracic'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity5 :: (MESH:D009369,Disease) :: ['stage III non-small cell lung cancer']
